CSPC Pharma Revenue, Profits - CHPTY Quarterly Income Statement

Add to My Stocks
$101.08 $0 (0%) CHPTY stock closing price Nov 29, 2017 (Closing)

Financial statements provide us with a way to gain insights and undertake the fundamental analysis of a company. Checking CSPC Pharma stock price alone is not sufficient. The income statement is a summary of the revenue or sales, expenses and profitability - shown as Net Income, or lack of it. Like any other income statement, the CHPTY income statement also itemizes revenue/sales, operating expenses, and profits/bottomline for a quarter or year and reflects a QoQ revenue growth of 7.11% when compared to the same period in the past. Revenue for year 2017 Q2 is $479.02M and has increased from $447.23M quarter on quarter as is evident when you compare the latest figures in the latest CSPC Pharma profit and loss statement with those of the prior corresponding period. Also see CSPC Pharma assets and CSPC Pharma free cash flow for a complete valuation of CHPTY stock.

View and download details of revenue and profits for CSPC Pharma for latest & last 40 quarters.
show more
Quarterly
Annual
View Previous Quarters
View Next Quarters
Fiscal year is Jan - Dec2017 Q22017 Q12016 Q42016 Q32016 Q22016 Q12015 Q4
CSPC Pharma Revenues or Net Sales
479.02M447.23M402M400.24M406.17M385.03M372.97M
Cost Of Goods Sold (COGS)-------
CSPC Pharma Gross Profit
-------
Research & Development Expense-------
Selling General & Admin Expense-------
Income Before Depreciation Depletion Amortization-------
Depreciation Depletion Amortization-------
Non Operating Income-------
Interest Expense-------
CSPC Pharma Pretax Income
-------
Provision for Income Taxes-------
MinorityInterest-------
Investment Gains Losses-------
Other Income-------
Income Before Extraordinaries & Disc Operations86.68M82.19M68.72M68.97M67.92M65.04M54.47M
Extraordinary Items & Discontinued Operations-------
CSPC Pharma Profit/ Loss (Net Income)
86.68M82.19M68.72M68.97M67.92M65.04M54.47M
Average Shares used to compute Diluted EPS121.08M121.08M121.02M119.27M118.2M118.27M118.26M
Average Shares used to compute Basic EPS121.07M121.05M121.02M119.27M118.2M118.27M118.26M
Income Before Nonrecurring Items86.68M82.19M68.72M68.97M67.92M65.04M54.47M
Income from Nonrecurring Items-------
CSPC Pharma Earnings Per Share Basic Net
0.720.680.570.580.570.550.46
CSPC Pharma Earnings Per Share Diluted Net
0.720.680.570.570.570.550.46
EPS Diluted Before Nonrecurring Items0.720.680.570.570.570.550.46
Preferred Dividends Acc Pd-------
Dividends Common-------
Dividend Per Share Common0.750.000.000.000.690.000.00
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Quarters
View Next Quarters

Click here to view our Grifols financial analysis

CSPC Pharma stock analysis involves checking at least a few of the important things like:

  • Topline: A growing topline, as seen from the CSPC Pharma revenue chart, as is the case with CSPC Pharma indicates a growing business. One needs to compare the QoQ topline or sales growth of CHPTY stock with its peers like GRFS stock and MKGAF stock to see if the growth compares well with what can be expected from a company in that industry.
  • Bottom line: The word bottom line comes because it is usually the last line of the income statement and refers to the actual profits after deducting all expenses from the revenues. CHPTY stock had a healthy bottom line growth.

The income statement is also called statement of revenue and expense. The CHPTY financials along with CSPC Pharma historical stock prices provide a lot of details about the firm.

CSPC Pharma Income Statement - Key Financial Ratios

PE Ratio (price earnings ratio)
39.8
PS Ratio (price sales ratio)
7.08
Net Profit Margin
18.1
Dividend Yield
0.74%

Other Income Statements - CSPC Pharmaceutical Group Ltd (ADR) Industry Peers

Grifols income statement, Merck KGAA income statement, Sagent Pharma income statement